Related references
Note: Only part of the references are listed.Losartan for treatment of epidermolysis bullosa: A new perspective
Jouni Uitto et al.
DERMATOLOGIC THERAPY (2021)
Investigational Treatments for Epidermolysis Bullosa
Ping-Chen Hou et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)
Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility
C. Has et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Losartan as disease modulating therapy for recessive dystrophic epidermolysis bullosa
Arun C. Inamadar
DERMATOLOGIC THERAPY (2020)
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms
Alexander Nystroem et al.
EMBO MOLECULAR MEDICINE (2015)
A Randomized, Open-Label, Dose-Response Study of Losartan in Hypertensive Children
Nicholas J. A. Webb et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Randomized, Double-Blind, Controlled Study of Losartan in Children with Proteinuria
Nicholas J. A. Webb et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Extracutaneous manifestations and complications of inherited epidermolysis bullosa Part I. Epithelial associated tissues
Jo-David Fine et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)